Autologous Immune Therapy - HUMARES GMBHhumares.de/files/fallbeispiele/ahit.pdf · Autologous Immune Therapy by Dr. med. Horst Kief Presentation Istanbul Okt 2012 . 2 Overview > Mode

AHIT TM Autologous Immune Therapy

by Dr. med. Horst Kief

Presentation Istanbul Okt 2012

2

Overview

> Mode of action > Malfunctioning > Facts and Figures > Introduction > History > Background > Indications

– Neurodermatitis, Psoriasis, Asthma

– Colitis

– Poliarthritis

– Hepatitis

– HIV

– Cancer > Culture Transformation Test (KTT) > Summary > Questions & Answers

H. Kief Istanbul 2012

3

> Retrieval of immune-modulation messengers

from the individual patient„s blood and urine

(cytokines)

> Controlled increase of autologous messengers

> Giving back autologous messengers to the individual

Mode of action


4

Malfunctioning immune system caused by:

> Personality structure

> Allergens

> Climate

Typical diseases

> Seborrhoic Eczema

> Allergic Rhinits

> Contact dermatitis

> Urticaria

Improvement

AHIT TM – Autologous Immune Therapy

> Genetic factors

> Environment

> Chronic Bronchitis

> Neurodermatitis

> Psoriasis

> Asthma


5

Lifetime prevalence allergic diseases

Source: Informationservice of environmental medicine , Germany

0%

2%

4%

6%

8%

10%

12%

14%

16%

18%

Alle

rgic rh

initis

Alle

rgic e

czem

a

Urtica

ria

Food allerg

ies

Bro

nchial asthm

a

Alle

rgic a

sthm

a

Neu

rode

rmatitis

all

West

East


6

Lifetime prevalence bronchial asthma, allergic coryza and urticaria

0,00%

2,00%

4,00%

6,00%

8,00%

10,00%

12,00%

14,00%

16,00%

18,00%

20,00%

22,00%

24,00%

20 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79

Age in years

Bronchial asthma

Allergic asthma

Allergic coryza

Urticaria

Source: Informationservice of environmental medicine , Germany


7

Lifetime prevalence allergic eczema, neurodermatitis, food allergies

0,0%

2,0%

4,0%

6,0%

8,0%

10,0%

12,0%

14,0%

16,0%

18,0%

20,0%

22,0%

20-29 30-39 40-49 50-59 60-69 70-79

Age in years

Allergic eczema

Neurodermatitis

Food allergies

Source: Umweltmedizinischer Informationsdienst, Germany


8

The Autologous Immune Therapy

How does the AHIT ™ work?


9

Reduction of eosinophilic cationic protein

0

5

10

15

20

25

30

35

40

EC

P in

µg/l

prior AHIT therapy 121 days after AHIT therapy

n = 31


10

Decrease of IgE with AHIT ™

0

500

1000

1500

2000

2500

3000

3500

4000

IgE

in

U/m

l

prior AHIT therapy 158 days after AHIT therapy

n = 37


Control of cytokines in Vaccine and serum of patients with an atopic disease

11

0

5

10

15

20

25

30

35

40

Pic

ogram

m

IL-2 IL-2R (x100) IL-8 (x10) y-INF (x100) GM-CSF

Untreated serum (5)

Initial effects (10)

Medication (11)

n = 11


12

Regulation effects of AHIT ™ on the immune system of patients affected with atopic diseases

IL2R ECP Suppr.Zell.

PATIENT IL2

IgE EOS gamma-Inf

IL2 IL2R

AHIT- Preparation

gamma-Inf IgE

IL2R ECP ident. Suppr. Cell

PATIENT IL2

IgE EOS gamma-Inf


13

Indications of AHIT ™

Neurodermatitis


14

Results of treating neurodermatitis

multicentre study

fullremission

41%

no improvement

7%improvement

11%

drastic improvement

41%

n = 139


15


long term study (2,5 years)

fullremission

37%

no improvement

8%improvement

11%

drastic improvement

44%n = 115


16

Success of the AHIT ™ therapy

about 8 years after therapy

strong improvement

18%

good improvement

23%

improvement

27%

slight improvement

19%

no improvement

13%

n = 135

Dissertation University of Heidelberg 1997


17


consumption of cortisone cream/month

0

20

40

60

80

100

120

140

160

180

nu

mb

er

of p

atie

nts

100-200g ca.100g ca.50g 1-50g nothing

before therapy

after therapy

n = 190


18


Consumption of skin care / month

0

20

40

60

80

100

120

140

160

180

200

nu

mb

er

of p

atie

nts

500-1000g 200-500g 100-200g 1-100g nothing

before therapy

after therapy

n = 231


19

Duration of disease, treatment and remission with AHIT ™ (neurodermatitis)

115

91,5

13

0 20 40 60 80 100 120 140

disease

treatment

remission after AHIT®

n = 231


20

Neurodermatitis – children

Time to fullremission: 8 month H. Kief Istanbul 2012

21


Time to remission: 7 month H. Kief Istanbul 2012

22


Long time remission: 5 years H. Kief Istanbul 2012

23


Time to fullremission: 6 month H. Kief Istanbul 2012

24


Time to fullremission: 1 year H. Kief Istanbul 2012

25


Control after 2 years of remission H. Kief Istanbul 2012

26


Time to full remission: 9 month H. Kief Istanbul 2012

27

Neurodermatitis – teenager


28

Neurodermatitis – teenager


29

Neurodermatitis – adults

Time to remission 8 month H. Kief Istanbul 2012

30


Long time remission over 15 years H. Kief Istanbul 2012

31


Long time remission, control after 1 year H. Kief Istanbul 2012

32



33



34


Sideeffects caused by cortisone occlusive bandage

Time to remission 5 month H. Kief Istanbul 2012

35

Neurodermatitis - KTT

The Culture-Transformation-Test

with patients suffering Neurodermatitis

Impact of antigens, toxins and allergens on the morphology and cell count of blood


36

KTT

raw data

Δ% granularity = amount of chromatophil biomaterial of Granulocytes and Lymphocytes.

Δ% RNA/DNA-concentration of Granulocytes and Lymphocytes.

Toxicity effects Δ% cell volume x Δ% cells per µl.

Δ% granularity , Δ% RNA / DNA and the toxicity effect are raw data.

The toxicity effect is most important.


37

Sensibility factors

Sensibility factor 1 includes the above raw data and transfroms them mathematically into a diagnostic utilizable result.

Sensibility factor 3 includes the variations of the numbers of Thrombocytes, Lymphocytes and Monocytes in addition to SF 1.

Sensibility factor 4 includes the data of SF 1 in addition to difference of cell counts of SF 3 as well as the variation of monocytes. It represents to an increasing degree the antigen- recognition of the cellular immune system.

Due to the affinity of different kinds of agents to particular cell families only the summary of all results deliver a comprehensive picture of the impact on the cellular immune system.


38


The following items can be tested:

Bakteria

- Borrelia - Sinusitis bacteria - Chlamydia - Staphylococci (D5) - Vibrio Cholerae - Streptococci (D5) - Corynebacteria - Tetanus - Diphteria - Typhus - Hämophilus (mono-culture) - Escherichia Coli, Morganella - Meningococci morganii, Proteus mirabilis, - Mycobacteria Klebsiella pneumoniae, - Mycoplasma Enterococcae faecaliae - Pneumococci as mix - Propionibacteria - Diphteria pertussis, Tetanus, - Proteobacteria Haemophilus as mixture - Pseudomonas - path. Colibacteria (ca. 60 - Serratia (D7) different strains)


39


Sinusitis bacteria:

Streptococcus pneumoniae (Typ I, II, III, V, VIII, XII), Streptococcus pyogenes group A, Streptococcus dysgalactiae group C, Enterococcus faecium, Enterococcus faecalis, Streptococcus group G, Staphylococcus aureus, Haemophilus influenza type B, Moraxella catarrhalis, Neisseria subflava var. flava, Neisseria subflava perflava, Klebsiella pneumoniae ss pneumoniae, Acinetobacter calcoaceticus as mixture.

Pneumococci:

Polysaccharides of serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F


40


Viruses Fungi

- Adenoviruses - Aspergillus fumigatus

- Cytomegalovirus - Aspergillus niger

- FSME - Candida

- Yellow fever - Mucor mucedo

- Influenza virus - Mucor racemosus /Aspergillus

- Hepatitis A (mono culture) niger (combination)

- Hepatitis A und B (combination) - Aspergillus fum., Mucor mucedo,

- Hepatitis A + Salmonella typh (combination) Penicillinum not., Pullularia pul.,

- Herpes virus Rhizopus nig., Serpula lac.

- Measles (mono culture) (combination)

- Measles, mumps, rubella viruses

- Papilloma virus

- Parapoxiviruses

- Poliovirus

- Rotaviruses

- Rubella (mono culture)

- rabies viruses


41


Allergens

- Alder - Middle bloomers

- Apple - Mite (acarine) - Barley - Mugwort - Birch - Mussel - Cat epithelia - Oat - Celery - Peanuts - Chicken - Pork - Cow„s milk - Rye - Dog epithelia - Salmon - Early Bloomers - Tomato - Eggs - Trout - Grains - Turkey - Grasses - Venom (bee) - Hazel - Venom (wasp) - Hazelnut - Wheat - Horse epithelia - Willow


42


Cumulative statistics of immune modulative effects on blood of patients suffering Neurodermatitis via different toxins and antigens

Δ% Granularity: amount of stainable bio-material of Granulocytes and Lymphocytes

-40

-30

-20

-10

0

10

20

30

40

1 ch

oler

a

5 influ

enza

8 diph

teria

, per

tuss

is, t

etan

us, p

olio, h

ae...

9 he

rpes

13 p

neum

ococ

ci

26 rot

aviru

s

27 e

sch.

coli, m

orga

n., p

rot.,

kle

bs.,

ente

ro...

.

28 b

orre

lia

29 c

hlam

ydia

39 a

carin

e fa

rin.

40 a

carin

e pt

eron

y.

51 a

sper

gillu

s fu

migat

us

55 c

at e

pith

elia

59 a

lder

62 o

at

65 g

rass

es /

grai

n

67 tr

ees

I / e

arly b

loom

ers

68 tr

ees

II / m

iddle

bloo

mer

s

70 fu

ngi II

n = 34


43



Δ% RNA/DNA-concentration of Granulocytes and Lymphocytes

-40

-30

-20

-10

0

10

20

30

40

1 ch

oler

a

2 he

patitis A

and

B

3 te

tanu

s

5 influ

enza

8 diph

teria

, per

tuss

is, t

etan

us, p

olio, h

aem

ophilia

9 he

rpes

13 p

neum

ococ

ci

14 d

ipht

eria

19 s

inus

itis

23 p

ropion

i bac

teria

25 p

rote

us vulga

ris

26 rot

aviru

s

27 e

sch.

coli, m

orga

n., p

rot.,

kle

bs.,

ente

ro. f

aeca

.

30 m

ycop

lasm

a

34 m

ycob

acte

ria

35 p

seud

omon

as

39 a

carin

e fa

rin.

40 a

carin

e pt

eron

y.

42 a

ppel

50 tr

out

51 a

sper

gillu

s fu

migat

us

55 c

at e

pith

elia

57 w

heat

65 g

rass

es /

grai

n

68 tr

ees

II / m

iddle

bloo

mer

s

70 fu

ngi II

71 c

ow's m

ilk

72 c

eler

y

n = 28


44



Toxicityeffect: Δ% number of cells / µl

-15-10-505

10152025303540

1 ch

olera

4 co

li D7

8 diph

teria

, per

tuss

is, tetan

us, ...

10 ty

phus

13 pneu

moc

occi

18 m

eningo

cocc

i

21 m

old

23 pro

pion

i bac

teria

26 ro

taviru

s

28 borre

lia

30 m

ycop

lasm

a

33 cytom

egalov

irus

39 aca

rine

farin

.

51 asp

ergillu

s fumigatus

54 dog

epith

elia

56 ra

bbit ep

ithelia

59 alder

63 birc

h

67 tr

ees I / ear

ly bloom

ers

71 cow

's m

ilk

n = 34


45


Cumulative presentation of immune modulating effects on blood of Neurodermatitis patients via different toxins and antigenes

KTT SF1: Δ% cell morphology of Granulocytes

-30

-20

-10

0

10

20

30

40

1 ch

oler

a

8 diph

teria

, pertu

ssis, t

etan

us, p

olio, h

aemoph

ilia

9 he

rpes

13 pneu

moc

occi

14 dip

hteria

19 sinus

itis

22 can

dida

27 esc

h.coli, m

organ

., pr

ot.,

kleb

s., e

nter

o. faec

a.

28 borre

lia

29 chlam

ydia

30 m

ycop

lasm

a

31 m

ucor

race

mos

a / a

sper

gillus nige

r

40 aca

rine pte

rony

.

50 tr

out

51 asp

ergillu

s fu

migat

us

55 cat

epith

elia

65 gra

sses

/ gr

ain

67 tr

ees I /

early

bloom

ers

68 tr

ees II

/ middle

bloo

mer

s

70 fu

ngi II

71 cow

's m

ilk

n = 35


46



KTT – SF3: Δ% of cell morphology and cell count

-60

-50

-40-30

-20

-10

0

10

2030

40

50

1 ch

oler

a

4 co

li D7

5 influ

enza

7 stap

hyloco

cci

8 diph

teria

, pertu

ssis, t

etan

us, p

olio,..

.

9 he

rpes

11 m

easles

, mum

ps, r

ubella

13 pneu

moc

occi

14 dip

hteria

19 sinus

itis

21 m

old

22 can

dida

23 pro

pion

i bact

eria

25 pro

teus

vulga

ris

26 ro

taviru

s

27 esc

h.coli, m

organ

., pr

ot.,

kleb

s., e

...

29 chlam

ydia

30 m

ycop

lasm

a

31 m

ucor

race

mos

a / a

sper

gillus nige

r

35 pse

udom

onas

39 aca

rine fa

rin.

40 aca

rine pte

rony

.

42 appl

e

50 tr

out

51 asp

ergillu

s fu

migat

us

52 m

ucor

muc

edo

55 cat

epith

elia

60 ry

e

62 oat

63 birc

h

64 m

ugwor

t

65 gra

sses

/ gr

ain

67 tr

ees I /

early

bloom

ers

68 tr

ees II

/ middle

bloo

mer

s

70 fu

ngi II

n = 31


47



KTT SF4: Δ% Granulocytes x Δ% Lymphocytes x Δ% Monocytes

-30

-20

-10

0

10

20

30

40

50

1 Chol

era

2 he

patitis A a

nd B

5 influ

enza

8 diph

teria

, pertu

ssis, t

etan

u..

9 he

rpes

13 pneu

moc

occi

19 sinus

itis

21 m

old

22 can

dida

23 pro

pion

i bact

eria

26 ro

taviru

s

27 esc

h.coli, m

organ

., pr

ot.,.

..

28 borre

lia

29 chlam

ydia

30 m

ycop

lasm

a

31 m

ucor

race

mos

a / a

sper

g...

33 cytom

egalo

viru

s

35 pse

udom

onas

39 aca

rine fa

rin.

40 aca

rine pte

rony

.

42 appe

ll

50 tr

out

51 asp

ergillu

s fu

migat

us

52 m

ucor

muc

edo

55 cat

epith

elia

57 w

heat

60 ry

e

62 oat

65 gra

sses

/ gr

ain

67 tr

ees I /

early

bloom

ers

68 tr

ees II

/ middle

bloo

mer

s

70 fu

ngi II

71 cow

's m

ilk

72 celer

y

n = 29


48

Diagnostic Value of KTT

Auto-immune disease caused tetany

Diagnosis via KTT-toxicity effect


49


MS: Status 1994 after 6 months AHIT ® 2006

Identification of triggering factors via Culture-Transformation-Test.

(Part-) Remission of Multiple Sclerosis


50


Remission of Morbus Boeck

Elimination of the secondary heart insuffiency (Cor bovinum).

Identification of triggering factors via Culture-Transformation-Test.


51

KTT – action chart

patient data

diagnosis

therapy

control

potential revision of diagnosis

humoral parameters

stimulation

culture

control

KTT

AHIT

Controlling of AHITTM


52


What is the value of the KTT?

1. The KTT procedurally rests on base values generated by state-of-art technical equipment. The difference of these base values is mathematically related to the “regular” blood picture and the depletion determined.

2. It detects stimulating, suppressing and toxic factors to the cellular immune system.

3. Many times the results are congruent with serologic lab tests and confirms or complements their information.

4. It helps to verify forgotten focal infections.


53


What is the value of the KTT?

5. It allows to detect toxic effects caused by bacteria and viruses.

6. Even exotic toxins and allergenes can be investigated.

7. It can be used as a follow-up of the autologous immune therapy.

8. Stimulative factors for an individually specific production of the AHITTM can be identified

9. It gains particular importance in the diagnosis and clarification of the genesis of many auto-immune diseases as well as other unexplained medical conditions.

10.It helps to determine the increasing virulence of different germs in mixed infections.


54


Are there any disadvanages to the KT-Test?

1. A relatively „young“ or successful vaccinaction with accordingly high titer of antibodies or a hypo-sensitization may result in a false positive reaction.

2. Due to numerous blood cultures the test is time-consuming.

3. Presently the test is not automated resulting in a time-consuming data entry.


55

Indications of AHIT™

Asthma


56

Results of treating asthma with AHIT™

no improvement

21%

improvement

11%

drastic improvement

32%

fullremission

36%

n = 84


57

Medicament consumption (asthma)

before and after AHIT ™

0

5

10

15

20

25

30

35

40

45

50

nu

mb

er

of

pa

tie

nts

antiallergica mediator

antagonists

secretolytics theophyline

derivates

beta-2-

mimetica

systemic

cortisone

cortisone

inhalation

antibiotica

before

after

n = 65


58

Asthma - KTT

Cumulative presentation of immune modulating effects on blood of asthma patients via different toxins and antigenes

Δ% Granularity: amount of stainable bio-material

-15

-10

-5

0

5

10

15

20

1 ch

oler

a

2 he

patitis A

u. B

5 influ

enza

8 diph

teria

, per

tuss

is, t

etan

us, p

olio, h

aem

ophilia

10 ty

phus

12 polio

13 pne

umoc

occi

19 sinus

itis

27 esc

h.co

li, m

orga

n., p

rot.,

klebs

., en

tero

. fae

ca.

40 aca

rine pt

eron

y.

41 to

mat

o

43 haz

elnu

t

47 tu

rkey

49 chick

en

50 tr

out

51 asp

ergillu

s fum

igat

us

61 bar

ley

62 oat

65 gra

sses

/ gr

ain

66 haz

el

68 tr

ees II / m

iddle bloo

mer

s

70 fu

ngi II

71 cow

's m

ilk

72 celer

y

80 egg

s

n = 15


59

Asthma - KTT



-15

-10

-5

0

5

10

15

20

25

2 he

patitis A u

. B

5 influ

enza

8 Diphte

rie, P

ertu

ssis, T

etan

us, P

olio, H

ämop

hilus

8 diph

teria

, pertu

ssis, t

etan

us, p

olio, h

aemop

hilia

10 ty

phus

13 pneu

moc

occi

19 sinus

itis

23 pro

pion

ibac

teria

27 esc

h.coli, m

organ

., pr

ot.,

kleb

s., e

nter

o. faec

a.

40 aca

rine pte

rony

.

51 asp

ergillu

s fu

migat

us

62 oat

65 gra

sses

/ gr

ain

68 tr

ees II

/ middle

bloo

mer

s

70 fu

ngi II

n = 15


60

Asthma - KTT


Toxicity effects: Δ% amount of cells/µl

-5

0

5

10

15

20

25

2 he

patitis A u

. B

5 influ

enza

6 stre

ptoco

cci

8 diph

teria

, pertu

ssis, t

etan

us, p

olio, h

aemop

hilia

9 he

rpes

10 ty

phus

11 m

easles

, mum

ps, r

ubella

13 pneu

moc

occi

15 tu

berculin

um

19 sinus

itis

21 m

old

22 can

dida

23 pro

pion

i bact

eria

27 esc

h.coli, m

organ

., pr

ot.,

kleb

s., e

nter

o. faec

a.

30 m

ycop

lasm

a

31 m

ucor

race

mos

a / a

sper

gillus nige

r

32 aden

oviru

s D6

34 m

ycob

acter

ia

36 ser

ra D

7

39 aca

rine fa

rin.

40 aca

rine pte

rony

.

44 pean

ut

48 m

usse

l

51 asp

ergillu

s fu

migat

us

52 m

ucor

muc

edo

65 gra

sses

/ gr

ain

67 tr

ees I /

early

bloom

ers

68 tr

ees II

/ middle

bloo

mer

s

72 celer

y

79 para

poxi-v

irus ovi

s 1:

100

n = 15


61

Asthma - KTT


KTT SF1: Δ% cell morphology of Granulocytes

-20

-15

-10

-5

0

5

10

15

20

1 ch

oler

a

4 co

li D7

5 influ

enza

6 stre

ptoco

cci

8 diph

teria

, pertu

ssis, t

etan

us, p

olio, h

aemop

hilia

9 he

rpes

10 ty

phus

13 pneu

moc

occi

14 dip

hteria

15 tu

berculin

um

16 lu

esinu

m

19 sinus

itis

25 pro

teus

vulga

ris

27 esc

h.coli, m

organ

., pr

ot.,

kleb

s., e

nter

o. faec

a.

39 aca

rine fa

rin.

51 asp

ergillu

s fu

migat

us

61 barle

y

65 gra

sses

/ gr

ain

70 fu

ngi II

72 celer

y

n = 30


62

Asthma - KTT


KTT – SF3: Δ% of cell morphology and cell count

-40

-30

-20

-10

0

10

20

30

1 Cho

lera

2 he

patitis A

u. B

4 co

li D7

5 influ

enza

6 stre

ptoc

occi

8 diph

teria

, per

tuss

is, t

etan

us, p

olio, h

aem

ophilia

10 ty

phus

11 m

easles

, mum

ps, r

ubel

la

12 p

olio

13 p

neum

ococ

ci

14 d

ipht

erie

19 s

inus

itis

22 c

andida

26 rot

aviru

s

27 e

sch.

coli, m

orga

n., p

rot.,

kle

bs.,

ente

ro. f

aeca

.

34 m

ycob

acte

ria

39 a

carin

e fa

rin.

40 a

carin

e pt

eron

y.

46 p

ork

51 a

sper

gillu

s fu

migat

us

62 o

at

65 g

rass

es /

grai

n

68 tr

ees

II / m

iddle

bloo

mer

s

70 fu

ngi II

n = 27


63

Asthma - KTT


KTT SF4: Δ% Granulocytes x Δ% Lymphocytes x Δ% Monocytes

-15

-10

-5

0

5

10

15

20

1 ch

olera

8 diph

teria

, per

tuss

is, t

etanu

s, p

olio, h

a...

13 p

neum

ococc

i

19 sin

usitis

23 p

ropio

nibact

eria

27 e

sch.

coli, m

organ

., pr

ot.,

kleb

s., e

nter..

51 a

sper

gillus

fum

igat

us

62 o

at

67 tr

ees I /

early

blo

omers

68 tr

ees II

/ middle

bloom

ers

70 fu

ngi II

n = 15


64


Polyarthritis


65

Primar chronic Polyarthritis

Improvement of mobility after 1,5 years H. Kief Istanbul 2012

66


Improvement of mobility after 3 month H. Kief Istanbul 2012

67


Improvement of mobility after 3 month H. Kief Istanbul 2012

68

Immunevasculitis

Fullremission after 3 month, no relapse since 15 years H. Kief Istanbul 2012

69


Colitis


70

Colitis ulcerosa pain-score

constant pain,

temporarily strong, 3-

cramps

constant pain

short phases 2-

of relief

periods of

pain and cramps 1-

outweigh

succession

of pain +/-

and relief

seasonal

light pain 1+

and cramps

sporadic

light 2+

pain

totally

painfree 3+

before during after

n = 14

n = 14

n = 13


71

Colitis mucosa and ulcerosa

Distribution of the frequency of symptoms

25

20

15

10

5

0

before therapy during therapy after therapy

n = 15

n = 15n = 15


72

Crohn„s disease pain score

constant pain,

temporarily strong, 3-

cramps

constant pain

short phases 2-

of relief

periods of

pain and cramps 1-

outweigh

succession

of pain +/-

and relief

seasonal

light pain 1+

and cramps

sporadic

light 2+

pain

totally

painfree 3+

before during after

n = 16

n = 16

n = 16


73

Crohn„s disease

Distribution of the frequency of symptoms

20

15

10

5

0

before therapy during therapy after therapy

n = 20

n = 20

n = 20


74

Indications of AHIT ™

Psoriasis


75

Comparative trial - Psoriasis

Fumaric Acid vs. AHIT TM

0

2

4

6

8

10

12

14

16

nu

mb

er

of

pa

tie

nts

0 30% 60% 90%

Improvement

Fumaric Acid

AHITTM


76

Psoriasis


77

Psoriasis


78

Psoriasis


79

Psoriasis - KTT

Cumulative presentation of immune modulating effects on blood of Psoriasis patients via different toxins and antigenes


-15

-10

-5

0

5

10

15

20

1 ch

olera

3 te

tanu

s

5 influ

enza

12 p

olio

13 p

neum

ococc

i

19 sin

usitis

21 m

old

24 cory

neba

cter

ia

27 e

sch.

coli, m

organ

., pr

ot.,

kleb

s., e

ntero

. fae

ca.

40 a

carin

e pt

eron

y.

65 g

rass

es / g

rain

68 tr

ees II

/ middle

bloom

ers

70 fu

ngi II

73 p

apillom

aviru

s 1:

50

n = 13


80

Psoriasis - KTT


Δ% Granularity: amount of stainable bio-material

-15

-10

-5

0

5

10

15

20

1 ch

olera

3 te

tanu

s

5 influ

enza

12 p

olio

13 p

neum

ococc

i

19 sin

usitis

21 m

old

24 cory

neba

cter

ia

27 e

sch.

coli, m

organ

., pr

ot.,

kleb

s., e

nter..

40 a

carin

e pt

eron

y.

65 g

rass

es / g

rain

68 tr

ees II

/ middle

bloom

ers

70 fu

ngi II

73 p

apillom

aviru

s 1:

50

n = 13


81

Psoriasis - KTT


Toxicity effects: Δ% amount of cells/µl

-10-5

05

10

152025

3035

1 ch

oler

a

3 te

tanu

s

5 in

fluen

za

6 st

rept

ococ

ci

8 di

phte

ria, p

ertu

ssis, t

etan

us, p

...

9 he

rpes

10 ty

phus

13 p

neum

ococ

ci

19 s

inus

itis

21 m

old

22 c

andi

da

23 p

ropi

onib

acte

ria

26 ro

taviru

s

27 e

sch.

coli, m

orga

n., p

rot.,

kle

...

29 c

hlam

ydia

30 m

ycop

lasm

a

31 m

ucor

race

mos

a / a

sper

gill..

36 s

erra

D7

39 a

carin

e fa

rin.

40 a

carin

e pt

eron

y.

51 a

sper

gillu

s fu

mig

atus

65 g

rass

es /

grain

67 tr

ees

I / e

arly b

loom

ers

68 tr

ees

II / m

iddl

e bl

oom

ers

70 fu

ngi I

I

n = 31


82

Psoriasis - KTT


KTT – SF1: Δ% cell morphology of Granulocytes

-40

-30

-20

-10

0

10

20

30

40

50

1 ch

oler

a

4 co

li D7

5 in

fluen

za

7 st

aphy

loco

cci

8 di

phte

ria, p

ertu

ssis, t

etan

us, p

olio, h

ae...

9 he

rpes

11 m

easles

, mum

ps, r

ubella

13 p

neum

ococ

ci

14 d

ipht

eria

19 sin

usitis

21 m

old

22 can

dida

23 p

ropi

oni b

acte

ria

25 p

rote

us v

ulga

ris

26 ro

taviru

s

27 e

sch.

coli, m

orga

n., p

rot.,

klebs

., en

tero

...

29 chl

amyd

ia

30 m

ycop

lasm

a

31 m

ucor

race

mos

a / a

sper

gillu

s ni

ger

35 p

seud

omon

as

39 a

carin

e fa

rin.

40 a

carin

e pt

eron

y.

42 a

pple

n = 31


83

Psoriasis - KTT


KTT– SF3: Δ% of cell morphology and cell count

-30

-20

-10

0

10

20

30

40

50

1 Cho

lera

2 he

patitis A

and

B

5 in

fluen

za

8 di

phte

ria, p

ertu

ssis, t

etan

us, p

olio, h

aem

...

9 he

rpes

13 p

neum

ococ

ci

19 sin

usitis

21 m

old

22 can

dida

23 p

ropi

oni b

acte

ria

26 ro

taviru

s

27 e

sch.

coli, m

orga

n., p

rot.,

klebs

., en

tero

. ...

28 b

orre

lia

29 chl

amyd

ia

30 m

ycop

lasm

a

31 m

ucor

race

mos

a / a

sper

gillu

s ni

ger

33 cyt

omeg

alov

irus

35 p

seud

omon

as

39 a

carin

e fa

rin.

n = 28


84

Psoriasis - KTT


KTT – SF4: Δ% Granulocytes x Δ% Lymphocytes x Δ% Monocytes

-30

-20

-10

0

10

20

30

40

1 ch

oler

a

8 di

phte

ria, p

ertu

ssis, t

etan

us, p

olio, h

ae...

9 he

rpes

13 p

neum

ococ

ci

14 d

ipht

eria

19 sin

usitis

22 can

dida

27 e

sch.

coli, m

orga

n., p

rot.,

klebs

., en

tero

...

28 b

orre

lia

29 chl

amyd

ia

30 m

ycop

lasm

a

31 m

ucor

race

mos

a / a

sper

gillu

s ni

ger

40 a

carin

e pt

eron

y.

n = 16


Cofactors of psoriasis

85

Antimicrobial peptides (AMPs) in psoriasis herds shows an activity against: 1. Escherichia coli 2. Staphylococcus aureus 3. Pseudomonas aeruginosa 4. Candida albicans 5. Acinetobacter Baumannii 6. Propionibacterium acnes 7. Streptococcus pyogenes 8. Streptococcus Pneumoniae 9. Enterococcus faecalis Statistically significant agreement with the results of the KT-test


Psoriasis

86 H. Kief Istanbul 2012

Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


Psoriasis


102

Incurable diseases with high chance for full remission by AHIT - Lungfibrosis - Myasthenia gravis - Post poliosyndrom



103


Summary/Conclusion

1. systemic treatment

2. wide range of indications

3. possible to treat multiple indications

4. no transferable infections


104


Thank you for you attention!


Documents

Autologous Immune Therapy - HUMARES GMBHhumares.de/files/fallbeispiele/ahit.pdf · Autologous Immune Therapy by Dr. med. Horst Kief Presentation Istanbul Okt 2012 . 2 Overview > Mode